Dendritic cell phenotype can be improved by certain chemotherapies and is associated with alterations to p21waf1/cip1

Cancer Immunology, Immunotherapy

Volumn 62, Issue 10, 2013, Pages 1553-1561

  Liu, Wai Man ^a   Scott, Katherine Ann ^a   Thompson, Mareike ^a   Dalgleish, Angus George ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Chemotherapy; Dendritic cells; Immune therapy; p21

Indexed keywords

ARTESUNATE; CAMPTOTHECIN; CD163 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLOPHOSPHAMIDE; CYTOKINE RECEPTOR; DOCETAXEL; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 8; LENALIDOMIDE; OXALIPLATIN; PROTEIN P21;

ARTICLE; CANCER CHEMOTHERAPY; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; COPY NUMBER VARIATION; DENDRITIC CELL; DRUG MECHANISM; LYMPHOCYTE PROLIFERATION; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

CELL DIFFERENTIATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DENDRITIC CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-4; MONOCYTES; NEOPLASMS; PHENOTYPE;

EID: 84885839092     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1456-0     Document Type: Article

References (28)

1. Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480(7378):480-489
2. Palucka K, Ueno H, Banchereau J (2011) Recent developments in cancer vaccines. J Immunol 186(3):1325-1331
3. Dalgleish AG (2011) Therapeutic cancer vaccines: why so few randomised phase III studies reflect the initial optimism of phase II studies. Vaccine 29(47):8501-8505
4. Liu WM, Dalgleish AG (2012) The potential beneficial effects of drugs on the immune response to vaccination. Semin Oncol 39(3):340-347
5. Liu WM, Dennis JL, Fowler DW, Dalgleish AG (2012) The gene expression profile of unstimulated dendritic cells can be used as a predictor of function. Int J Cancer 130(4):979-990
6. Lanza F, Castagnari B, Rigolin G, Moretti S, Latorraca A, Ferrari L, Bardi A, Castoldi G (1997) Flow cytometry measurement of GM-CSF receptors in acute leukemic blasts, and normal hemopoietic cells. Leukemia 11(10):1700-1710
7. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE (1999) The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 17:701-738
8. Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13(12):1501-1512
9. Sherr CJ (1996) Cancer cell cycles. Science 274(5293):1672-1677
10. Coqueret O (2003) New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 13(2):65-70
11. Santiago-Raber ML, Lawson BR, Dummer W, Barnhouse M, Koundouris S, Wilson CB, Kono DH, Theofilopoulos AN (2001) Role of cyclin kinase inhibitor p21 in systemic autoimmunity. J Immunol 167(7):4067-4074
12. Jackson SK, DeLoose A, Gilbert KM (2001) Induction of anergy in Th1 cells associated with increased levels of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1. J Immunol 166(2):952-958
13. Gazitt Y, Reddy SV, Alcantara O, Yang J, Boldt DH (2001) A new molecular role for iron in regulation of cell cycling and differentiation of HL-60 human leukemia cells: iron is required for transcription of p21(WAF1/CIP1) in cells induced by phorbol myristate acetate. J Cell Physiol 187(1):124-135
14. Kramer JL, Baltathakis I, Alcantara OS, Boldt DH (2002) Differentiation of functional dendritic cells and macrophages from human peripheral blood monocyte precursors is dependent on expression of p21 (WAF1/CIP1) and requires iron. Br J Haematol 117(3):727-734
15. Jonuleit H, Kühn U, Müller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH (1997) Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27(12):3135-3142
16. Liu WM, Fowler DW, Smith P, Dalgleish AG (2010) Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 102(1):115-123
17. Tuana G, Volpato V, Ricciardi-Castagnoli P, Zolezzi F, Stella F, Foti M (2011) Classification of dendritic cell phenotypes from gene expression data. BMC Immunol 12:50-62
18. Shortman K, Naik SH (2007) Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 7(1):19-30
19. Guthridge MA, Powell JA, Barry EF, Stomski FC, McClure BJ, Ramshaw H, Felquer FA, Dottore M, Thomas DT, To B, Begley CG, Lopez AF (2006) Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switch. EMBO J 25(3):479-489
20. Sallusto F, Lanzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179(4):1109-1118
21. Roy KC, Bandyopadhyay G, Rakshit S, Ray M, Bandyopadhyay S (2004) IL-4 alone without the involvement of GM-CSF transforms human peripheral blood monocytes to a CD1a(dim), CD83(+) myeloid dendritic cell subset. J Cell Sci 117(16):3435-3445
22. Conti L, Cardone M, Varano B, Puddu P, Belardelli F, Gessani S (2008) Role of the cytokine environment and cytokine receptor expression on the generation of functionally distinct dendritic cells from human monocytes. Eur J Immunol 38(3):750-762
23. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, Mahmoudi A, Cathers B, Rychak E, Gaidarova S, Chen R, Schafer PH, Handa H, Daniel TO, Evans JF, Chopra R (2012) Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26(11):2326-2335
24. Motoshima H, Goldstein BJ, Igata M, Araki E (2006) AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 574(1):63-71
25. Lee KM, Jo S, Kim H, Lee J (1813) Park CS (2011) Functional modulation of AMP-activated protein kinase by cereblon. Biochim Biophys Acta 3:448-455
26. ® immunomodulatory compounds Lenalidomide and Pomalidomide. Immunology. doi: 10.1111/imm.12087
27. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H (2005) Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105(7):2862-2868
28. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM (2005) Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11(18):6713-6721